Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00832221 |
The aim of this study is to relate pharmacokinetics of two different formulations of quetiapine to PET measured receptor occupancy in the brains of healthy subjects.
Condition | Intervention | Phase |
---|---|---|
Depression |
Drug: SEROQUEL XR (quetiapine) Drug: SEROQUEL IR (quetiapine) Drug: radioligand [11C]raclopride |
Phase I |
Study Type: | Interventional |
Study Design: | Basic Science, Non-Randomized, Open Label, Single Group Assignment, Pharmacokinetics Study |
Official Title: | An Open Label, 1-sequence Cross-over, Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Receptor Occupancy of Quetiapine Fumarate Immediate Release (SEROQUEL®) With Quetiapine Fumarate Extended Release (SEROQUEL XR®) in Healthy Male Volunteers |
Estimated Enrollment: | 10 |
Study Start Date: | January 2009 |
Estimated Study Completion Date: | June 2009 |
Estimated Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator |
Drug: SEROQUEL XR (quetiapine)
repeated dose of oral tablets, 8 times per subject
Drug: radioligand [11C]raclopride
single dose of iv admin, 5 times per subject
|
2: Active Comparator |
Drug: SEROQUEL IR (quetiapine)
repeated dose of oral tablets, 4 times per subject
Drug: radioligand [11C]raclopride
single dose of iv admin, 5 times per subject
|
Ages Eligible for Study: | 20 Years to 45 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contact: AstraZeneca Clinical Study Information | 1-800-236-9933 | information.center@astrazeneca.com |
Sweden | |
Research Site | Recruiting |
Stockholm, Sweden |
Principal Investigator: | Ingemar Bylesjö, MD, PhD | AstraZeneca Clinical Pharmacology Unit, Stockholm, Sweden |
Study Director: | Sophia Bengtsson | AstraZeneca R&D, Södertälje, Sweden |
Responsible Party: | AstraZeneca ( Märta Segerdahl, MD, PhD, Medical Science Director, Clinical Discovery Team ) |
Study ID Numbers: | D1443C00038, EudractCT 2008-006553-40 |
Study First Received: | January 29, 2009 |
Last Updated: | August 18, 2009 |
ClinicalTrials.gov Identifier: | NCT00832221 History of Changes |
Health Authority: | Sweden: Medical Products Agency |
PET Phase 1 Depression |
SEROQUEL Positron Emission Tomography Drug profile comparison |
Neurotransmitter Agents Depression Tranquilizing Agents Psychotropic Drugs Central Nervous System Depressants Healthy Depressive Disorder Antipsychotic Agents |
Behavioral Symptoms Quetiapine Dopamine Mental Disorders Raclopride Mood Disorders Dopamine Agents |
Neurotransmitter Agents Depression Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants Dopamine Antagonists Depressive Disorder Antipsychotic Agents |
Pharmacologic Actions Behavioral Symptoms Quetiapine Mental Disorders Therapeutic Uses Raclopride Mood Disorders Dopamine Agents Central Nervous System Agents |